Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 14(7)2022 06 28.
Article in English | MEDLINE | ID: mdl-35891403

ABSTRACT

Polymicrobial pneumonias occur frequently in cattle, swine, and sheep, resulting in major economic losses. Individual pathogens comprising these complex infections may be mild on their own but can instead exhibit synergism or increase host susceptibility. Two examples of such pathogens, Mycoplasma ovipneumoniae (M. ovipneumoniae) and influenza D viruses (IDVs), naturally infect domestic sheep. In sheep, the role of M. ovipneumoniae in chronic nonprogressive pneumonia is well-established, but the pathogenesis of IDV infection has not previously been studied. We utilized a specific-pathogen-free sheep flock to study the clinical response to IDV infection in naïve vs. M. ovipneumoniae-exposed lambs. Lambs were inoculated intranasally with M. ovipneumoniae or mock infection, followed after four weeks by infection with IDV. Pathogen shedding was tracked, and immunological responses were evaluated by measuring acute phase response and IDV-neutralizing antibody titers. While lamb health statuses remained subclinical, M. ovipneumoniae-exposed lambs had significantly elevated body temperatures during IDV infection compared to M. ovipneumoniae-naïve, IDV-infected lambs. Moreover, we found a positive correlation between prior M. ovipneumoniae burden, early-infection IDV shedding, and IDV-neutralizing antibody response. Our findings suggest that IDV infection may not induce clinical symptoms in domestic sheep, but previous M. ovipneumoniae exposure may promote mild IDV-associated inflammation.


Subject(s)
Communicable Diseases , Mycoplasma ovipneumoniae , Orthomyxoviridae Infections , Orthomyxoviridae , Pneumonia , Sheep Diseases , Thogotovirus , Animals , Antibodies, Neutralizing , Cattle , Orthomyxoviridae Infections/veterinary , Sheep , Swine
3.
Nat Commun ; 11(1): 983, 2020 02 20.
Article in English | MEDLINE | ID: mdl-32080183

ABSTRACT

Endosomal sequestration of lipid-based nanoparticles (LNPs) remains a formidable barrier to delivery. Herein, structure-activity analysis of cholesterol analogues reveals that incorporation of C-24 alkyl phytosterols into LNPs (eLNPs) enhances gene transfection and the length of alkyl tail, flexibility of sterol ring and polarity due to -OH group is required to maintain high transfection. Cryo-TEM displays a polyhedral shape for eLNPs compared to spherical LNPs, while x-ray scattering shows little disparity in internal structure. eLNPs exhibit higher cellular uptake and retention, potentially leading to a steady release from the endosomes over time. 3D single-particle tracking shows enhanced intracellular diffusivity of eLNPs relative to LNPs, suggesting eLNP traffic to productive pathways for escape. Our findings show the importance of cholesterol in subcellular transport of LNPs carrying mRNA and emphasize the need for greater insights into surface composition and structural properties of nanoparticles, and their subcellular interactions which enable designs to improve endosomal escape.


Subject(s)
Cholesterol/analogs & derivatives , Lipids/chemistry , Nanoparticles/chemistry , RNA, Messenger/administration & dosage , Animals , Biological Transport, Active , Cell Line , Cholesterol/chemistry , Cryoelectron Microscopy , Endosomes/metabolism , HEK293 Cells , HeLa Cells , Humans , Mice , Nanoparticles/ultrastructure , RAW 264.7 Cells , RNA, Messenger/genetics , Sitosterols/chemistry , Transfection , X-Ray Diffraction
4.
Mol Ther ; 26(8): 2034-2046, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29910178

ABSTRACT

The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR). mRNA therapy via nanoparticle delivery represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia. We deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells, resulting in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day 3 post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response is superior to liposomal CFTR DNA delivery and is comparable with outcomes observed in the currently approved drug ivacaftor. LNP-cmRNA-based systems represent a powerful platform technology for correction of cystic fibrosis and other monogenic disorders.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/therapy , Genetic Therapy/methods , RNA, Messenger/administration & dosage , Administration, Intranasal , Animals , Cell Line , Cystic Fibrosis/genetics , Disease Models, Animal , Epithelial Cells/cytology , Epithelial Cells/metabolism , Female , Humans , Mice , Nanoparticles/chemistry , RNA, Messenger/chemistry , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...